The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 04, 2017
Filed:
Jan. 22, 2015
Applicant:
Biogen Idec MA Inc., Cambridge, MA (US);
Inventors:
Leonid Gorelik, Quincy, MA (US);
Alexey Lugovskoy, Woburn, MA (US);
Assignee:
Biogen MA Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/569 (2006.01); C07K 16/08 (2006.01); G01N 33/53 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56983 (2013.01); C07K 16/081 (2013.01); C07K 2317/33 (2013.01); G01N 2333/025 (2013.01); G01N 2469/20 (2013.01); G01N 2800/28 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01);
Abstract
Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.